文献速递肿瘤 PET/CT

[18F]PSMA-1007 PET/CT 在前列腺癌初始分期中的效能:系统评价与荟萃分析

Efficacy of [18F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis.
PubMed 文献 · J Nucl Med · 2026-01-02

患者水平T分期(前列腺外侵犯)汇总敏感度54%(95%CI 46%-63%)、特异度92%(95%CI 76%-98%);N分期(淋巴结转移)汇总敏感度42%(95%CI 28%-57%)、特异度94%(95%CI 90%-97%);M分期敏感度优于所有其他 tested 传统影像模态。结论认为[18F]PSMA-1007 PET/CT 在T、N、M分期中提供高敏感度和特异度,可在治疗前单次完成无创初始分期。

要点

  • 患者水平T分期(前列腺外侵犯)汇总敏感度54%、特异度92%。
  • 患者水平N分期(淋巴结转移)汇总敏感度42%、特异度94%。
  • M分期敏感度优于所有其他 tested 传统影像模态。

核心结论

  • [18F]PSMA-1007 PET/CT 与组织病理学对照,在前列腺癌T、N、M初始分期中提供高敏感度和特异度。
  • 该检查可在治疗前通过单次操作完成无创的T、N、M初始分期。

研究设计与样本

  • 系统评价与荟萃分析,系统检索PubMed纳入[18F]PSMA-1007用于前列腺癌初始分期的临床试验(前瞻性和回顾性研究)。
  • 纳入文献以组织病理学为对照,并报告敏感度和特异度的离散值。

主要发现

  • 患者水平T分期(前列腺外侵犯)基于3项研究的荟萃分析:汇总敏感度54%(95%CI 46%-63%),汇总特异度92%(95%CI 76%-98%)。
  • 患者水平N分期(淋巴结转移检测)基于5项研究的荟萃分析:汇总敏感度42%(95%CI 28%-57%),汇总特异度94%(95%CI 90%-97%)。
  • 患者水平M分期敏感度方面,[18F]PSMA-1007 PET/CT 优于所有其他 tested 传统影像模态。

关键数值与推荐

  • T分期(前列腺外侵犯,患者水平):汇总敏感度54%(95%CI 46%-63%),汇总特异度92%(95%CI 76%-98%)。
  • N分期(淋巴结转移,患者水平):汇总敏感度42%(95%CI 28%-57%),汇总特异度94%(95%CI 90%-97%)。

临床怎么用

  • 对于前列腺癌初始分期,可考虑使用[18F]PSMA-1007 PET/CT 以单次操作无创评估T、N、M分期。
  • 判读T分期前列腺外侵犯时需注意敏感度中等(54%),特异度较高(92%)。
  • 判读N分期淋巴结转移时需注意敏感度较低(42%),特异度较高(94%)。

局限性

  • T分期荟萃分析仅基于3项研究,N分期荟萃分析仅基于5项研究。
  • M分期仅1项研究(79例患者)报告,未提供汇总敏感度与特异度数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Staging of prostate carcinoma (PCa) still largely relies on histopathologic examination of prostate tissue. In the last few years, PET/CT with radiotracers that target the prostate-specific membrane antigen (PSMA) has emerged as a noninvasive and sensitive method for staging of PCa. Compared with [68Ga]PSMA-11, [18F]PSMA-1007 is a relatively new radiotracer for PSMA PET/CT with favorable characteristics such as a longer physical half-life, reduced bladder background uptake, and improved availability due to production off-site. The objective of this systematic review and metaanalysis is to summarize the efficacy of [18F]PSMA-1007 in primary T, N, and M staging of PCa in comparison to histopathology. Methods: Clinical trials on primary staging of PCa with [18F]PSMA-1007 (both prospective and retrospective studies) were identified by a systematic search in PubMed. Relevant literature used histopathology as a comparator and reported discrete values for sensitivity and specificity. A metaanalysis assessed differences in diagnostic parameters. Results: Nineteen studies were included in this review: 10 studies reported on T staging (739 patients), 8 studies reported on N staging (865 patients), and 1 study reported on M staging (79 patients). For T staging, our metaanalyses of extraprostatic extension on a patient level based on 3 studies revealed a pooled sensitivity of 54% (95% CI, 46%-63%) and a pooled specificity of 92% (95% CI, 76%-98%). For N staging, our metaanalyses on detection of lymph node metastases on a patient level based on 5 studies revealed a pooled sensitivity of 42% (95% CI, 28%-57%) and a pooled specificity of 94% (95% CI, 90%-97%). In terms of sensitivity for M staging on a patient level, [18F]PSMA-1007 PET/CT outperformed all other tested conventional imaging modalities. Conclusion: PET/CT imaging with [18F]PSMA-1007 provides high sensitivity and specificity in T, N, and M staging of PCa when compared with histopathology. It offers the possibility to perform noninvasive primary T, N, and M staging before treatment in a single procedure.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rahbar K, Giesel FL, Herrmann K, et al. Efficacy of [18F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis. J Nucl Med. 2026. PMID: 41130789. doi:10.2967/jnumed.125.269818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。